SER (Serina Therapeutics) Shareholder Yield % : -92.62% (As of Mar. 2026)


SER Serina Therapeutics Inc SER
12 GF Score
Price $1.97
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics Shareholder Yield %?

Serina Therapeutics SER +8.84% 12 Shareholder Yield % is -92.62% as of Mar. 2026. GuruFocus rates SER with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,299 Biotechnology companies, Serina Therapeutics ranks worse than 94.07% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Serina Therapeutics's Shareholder Yield % was -92.62%.


Serina Therapeutics  (AMEX:SER) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Serina Therapeutics Shareholder Yield % Related Terms


Serina Therapeutics Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Serina Therapeutics's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics Shareholder Yield % Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
0.00 0.00 0.00 -16.55 -2.72

Serina Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.79 0.27 2.53 -2.72 -86.98

SER vs NRSN, IGC, PVCT: Shareholder Yield % Comparison

For the Biotechnology subindustry, Serina Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Serina Therapeutics Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's Shareholder Yield % falls into.


SER
12GF Score
Serina Therapeutics Inc SER
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics Shareholder Yield % Calculation

Serina Therapeutics's Shareholder Yield % for the quarter that ended in Mar. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-99.21 %+12.23 %
=-86.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -92.62% mean?
Serina Therapeutics (SER) has a Shareholder Yield % of -92.62% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Serina Therapeutics and its competitors. According to the industry distribution chart, Serina Therapeutics ranks #1222 out of 1299 companies in the Biotechnology industry, placing it in the top 94.1%.
Is Serina Therapeutics' Shareholder Yield % too high?
Serina Therapeutics' current Shareholder Yield % is -92.62%. Based on the distribution chart, Serina Therapeutics ranks #1222 out of 1299 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Serina Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' Shareholder Yield % compare to NRSN and IGC?
According to the Biotechnology industry distribution chart, Serina Therapeutics ranks #1222 out of 1299 companies for Shareholder Yield %. This places Serina Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Serina Therapeutics and its competitors. Serina Therapeutics's current Shareholder Yield % is -92.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (SER) has a current Shareholder Yield % of -92.62%. The current Shareholder Yield % is -92.62%. Serina Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Serina Therapeutics (SER), the current Shareholder Yield % is -92.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Serina Therapeutics Business Description

Other Exchanges 2BO:Germany
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
12GF Score

Get the complete analysis for SER

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.97
Price